Global natural killer (NK) cell treatments include characteristics like a growing need for improved therapeutic choices, which would hinder manufacturers from releasing new products into the market, improving its higher demand investment in R&D contributes to the market expansion. Several research studies are now being conducted, which is anticipated to give manufacturers a competitive edge as they develop novel natural killer (NK) cell therapies that will open up a variety of new prospects in the natural killer (NK) cell therapeutics market. However, unfavourable & insufficient reimbursement conditions and negative side effects of treatments are anticipated to hinder the market’s growth throughout the forecast period.
What is Natural Killer (NK) Cell Therapeutics?
An important part of immune activation against aberrant cells is played by the specialised immune effector cell type known as the natural killer (NK) cell. NK cell activation is controlled by the contact of NK receptors with target cells, irrespective of antigen processing and presentation, in contrast to the steps necessary for T cell activation. The NK cell has attracted a lot of interest in the realm of cancer immunotherapy due to very simple signals for activation. A lot of initiatives are being made to create and design NK cell-based cancer immunotherapy. In this review, we provide our current knowledge of the biology of NK cells, examine the pre-clinical and clinical development of NK cell-based therapeutics, as well as their advancement, difficulties, and prospects for the future.
- The key market companies are creating innovative medicines like NK cell therapy (unmodified), CAR-NK cell therapy (modified), and NK cell engager as a result of an increasing focus on NK cell therapies research globally.
- For instance, the market for NK cell therapies is now being negatively impacted by the 79 active clinical studies for NK cell therapeutics for various indications, including acute myeloid leukaemia, hematologic malignancies, hepatocellular carcinoma, and peripheral T-cell lymphoma.
Browse for more information
Impact of COVID-19
- Governments imposed lockdowns due to the epidemic, which severely impeded NK cell therapeutic research and clinical development. This condition, which was mostly seen up until Q2 2021, had a detrimental effect on the market for NK cell treatments globally and decreased the number of preclinical and clinical studies for the product candidates. The main cause has been the challenging patient recruitment process for the ongoing clinical trials, which will affect the drug’s release schedules.
- The research and clinical development of NK cell therapies have been severely hampered by the COVID-19 pandemic. Companies involved in NK cell treatments have shifted their emphasis to the study and development of medications used to treat COVID-19 in order to assist governments and communities in establishing a new normal around the world.
- The NK cell treatment (unmodified) segment in the global NK cell therapeutics market is estimated to dominate the market during the forecast period and is expected to have a share of 57.82%. The sector comprises NK cell therapies under development that are generated from allogeneic or commercially available immunotherapy that kills cancer.
- The goal of the global natural killer (NK) cell therapies market is to slow the spread of the illness. According to Data Bridge Market Research, the global market for natural killer (NK) cell treatments would expand at a CAGR of 40.9% from 2022 to 2029.
- Market participants implement a range of strategic activities, including, among others, acquisition, expansion, and partnership. These activities aid them in expanding the company’s product line, which broadens the market and increases consumer demand for the company’s goods, finally enabling the players to generate the highest possible income.
- These strategic measures are being implemented by leading market participants in an effort to improve business operations and increase market profitability as demand for effective and inexpensive natural killer (NK) cell immunotherapy rises globally.
Approximately 3000 business divisions and different countries have been covered by the over 21000 industry studies that The Data Bridge Market Research Company has released. The studies make use of 150,000 datasets, in-depth secondary analysis, and unique insights from interviews with top businesspeople. The studies have been updated with a thorough study of COVID-19’s effects on various markets.